Drug Testing Industry Tests Positive for Cannabis Dependence

WASHINGTON, D.C. — America’s drug-testing industry has issued an emergency earnings warning after discovering that cannabis reform may reduce demand for businesses whose principal service is locating evidence of cannabis use inside other people’s urine.

The National Drug and Alcohol Screening Association, or NDASA, is asking a federal appeals court to freeze the Trump administration’s partial rescheduling of marijuana. Its legal filings warn that recognizing state-licensed medical cannabis under Schedule III could cause employers to abandon marijuana testing, force testing providers to perform more complicated reviews and drive smaller medical review officer practices out of business.

The numbers are not buried in a leaked spreadsheet or whispered by a nervous executive beside the shrimp tower at an industry conference. NDASA’s attorneys put them directly into a federal court filing. Marijuana-positive results are reportedly the largest source of revenue for medical review officer practices, and rescheduling could produce “at least a 35% decline” in that revenue within six to twelve months. NDASA also estimates that more than 700 member businesses could collectively spend over $700,000 revising their workplace drug-testing policies.

That is not an accusation from cannabis lobbyists.

That is the business model describing itself under oath.

The Urine Industrial Complex Issues a Going-Concern Warning

For decades, federal marijuana prohibition has supported a sprawling ancillary market consisting of laboratories, specimen collectors, medical review officers, policy consultants, training providers, background-screening firms and attorneys paid to help employers determine whether an employee interacted with cannabis at some point during the useful life of a refrigerator.

This ecosystem presents itself as workplace safety infrastructure. Its financial statements, however, appear increasingly dependent on a product that does not establish whether someone was impaired at work, endangered a coworker or did anything more operationally significant than consume cannabis days or weeks before surrendering a cup of piss to a stranger holding a clipboard.

That distinction has never been especially profitable.

A test for current impairment would answer a difficult question involving behavior, timing, dosage, tolerance and actual job performance. A metabolite test answers a much easier one: has this person used cannabis recently enough for chemistry to remain detectable?

The second question produces cleaner paperwork.

It also produces more customers.

America therefore built a workplace safety industry around detecting yesterday because detecting danger today was complicated.

Now, one limited federal reform threatens to introduce nuance into the transaction, and the people selling the transaction are warning a court that nuance may be fatal to quarterly revenue.

Schedule I Was the Subscription Model

In April, Acting Attorney General Todd Blanche moved FDA-approved marijuana products and marijuana covered by qualifying state medical licenses from Schedule I to Schedule III. The Justice Department simultaneously launched an administrative hearing on the broader proposal to reschedule marijuana nationwide. The April order did not legalize adult-use cannabis, remove marijuana from the Controlled Substances Act or convert dispensary loyalty points into federally insured currency.

It did something more dangerous to the drug-testing sector.

It acknowledged lawful medical use.

Schedule I offered the industry a beautifully uncomplicated recurring-revenue model. Marijuana had no accepted medical use under federal law. A positive result was therefore a positive result. There was no federally recognized patient status to investigate, no state medical authorization to consider and no awkward conversation about whether a worker’s off-duty treatment should be handled differently from workplace intoxication.

The federal government supplied the assumption.

Testing companies supplied the cup.

Employers supplied the employee.

Nobody in the middle had to establish impairment because Schedule I had already converted the presence of a metabolite into a character reference.

Under that system, cannabis prohibition functioned like enterprise software. The government maintained the legal architecture, employers purchased compliance and workers provided the data involuntarily.

NDASA is now warning that one portion of the federal operating system has been updated without preserving backward compatibility for the urine vendors.

The 35 Percent THC Revenue Cliff

The most extraordinary section of NDASA’s argument is not its warning about safety. Employers have legitimate obligations to prevent impairment in transportation, construction, healthcare, manufacturing and other safety-sensitive work. Cannabis can impair judgment and reaction time, and no serious reform advocate needs to pretend otherwise.

The extraordinary section is the industry’s calculation of irreparable harm.

NDASA argues that marijuana-positive results are the largest source of medical review officer revenue. If employers stop purchasing those tests, the association predicts revenue could fall by at least 35 percent in six to twelve months. Providers that continue processing marijuana results may face additional work determining whether a positive is connected to state-authorized medical use, creating what the filing describes as a combination of falling revenue and rising costs that could eliminate smaller practices.

In ordinary financial reporting, losing 35 percent of revenue because customers no longer value your flagship product is called market risk.

In prohibition economics, it is called irreparable harm.

Imagine Marlboro asking a federal court to halt nicotine reform because fewer smokers would damage tobacco revenues. Imagine a private prison company arguing that sentencing reform must be suspended because empty beds create unrecoverable losses. Imagine Spirit Halloween demanding the government preserve commercial vacancy because successful tenants threaten its seasonal footprint.

The argument would be grotesque.

It would also be honest.

NDASA’s filing effectively asks the court to consider the financial health of companies that monetize marijuana-positive test results when deciding whether marijuana should remain under the harshest federal classification. The industry is not merely commenting on public policy. It is submitting its own dependency on prohibition as evidence that prohibition must continue.

The drug-testing sector has become addicted to cannabis.

Fortunately, NDASA knows several laboratories.

The Test Does Not Know Whether You Were High

Urine testing can detect marijuana metabolites long after the impairing effects of cannabis have ended. Federal transportation-safety guidance acknowledges that THC-related compounds may remain detectable for days or weeks, and federal researchers have repeatedly noted that toxicology results showing cannabis exposure do not, by themselves, prove impairment at a particular moment.

This does not make drug testing useless. It makes the purpose of the test critically important.

Testing workers in federally regulated safety-sensitive positions is different from screening a graphic designer, warehouse applicant, hotel receptionist or accounts-payable specialist for conduct that occurred away from work. One program is at least connected to a defined safety regime. The other often survives because corporate policy was written during the Reagan administration and nobody wants to be the HR director who asks why Sheila in payroll must prove she spent Saturday night according to company values.

The drug-testing industry benefits when employers blur use and impairment into one billable category.

A marijuana metabolite does not tell a medical review officer whether the donor arrived at work impaired. It does not identify the hour of consumption. It does not establish poor performance. It does not prove unsafe conduct. It certainly does not explain why Steve from regional operations has attended six Zoom meetings without learning how to unmute himself.

It identifies prior exposure.

That can matter under a specific policy, but it is not an impairment test merely because the invoice says “workplace safety” at the top.

Alcohol policy generally focuses on whether someone is impaired when impairment matters. Cannabis policy has spent decades punishing the biological afterimage.

That afterimage is apparently worth 35 percent of somebody’s revenue.

Jo McGuire Rings the Alarm Bell

NDASA Executive Director Jo McGuire testified during the DEA’s rescheduling hearing, where the association was designated Complainant No. 1. NDASA said McGuire and consultant Patrice Kelly would explain the implications of Schedule III for federally mandated testing, transportation safety, workplace policies and the operation of SAMHSA-certified laboratories.

The association also used the occasion to solicit donations.

Its chairman, Mark Magsam, told members that legal counsel, expert witnesses, research and direct engagement with federal agencies required sustained financial support. He asked the drug-testing community to fund NDASA’s advocacy so the organization could continue representing the industry in decisions affecting workplace safety.

The sequence was immaculate.

First, warn that marijuana reform threatens drug-testing revenue.

Then, request money from the drug-testing industry to fight marijuana reform.

This is vertical integration.

NDASA does not merely represent companies that profit from cannabis prohibition. It has developed a prohibition product of its own, complete with advocacy subscriptions, expert-witness expenses and an urgent call to “support the industry today so we can help protect tomorrow.”

Tomorrow, in this formulation, is a place where every employer continues purchasing marijuana tests, every positive result continues producing medical-review revenue and no reform proceeds without first passing an economic-impact study on the people paid to enforce the old policy.

It is difficult to imagine a safer workplace than one where the compliance vendor never experiences financial uncertainty.

The Department of Justice Discovers Capitalism

The Justice Department’s response was unusually direct for a federal filing written by people who ordinarily describe a fire as an “unplanned thermal event.”

DOJ argued that NDASA and a pharmaceutical company involved in the same litigation were invoking “pocketbook interests served by keeping all marijuana in schedule I.” It said Congress enacted the Controlled Substances Act to regulate drugs for public health, research and medical treatment, not to guarantee drug screeners a permanent source of marijuana-testing income.

The government also challenged NDASA’s standing. According to DOJ, the association offered generalized predictions rather than concrete harm to identified members. Employers might independently decide to stop testing for marijuana. Testing providers might choose whether to absorb additional review costs or pass them to clients. Those business decisions, the government argued, would not necessarily be injuries caused directly by the rescheduling order.

NDASA responded that the government’s pocketbook argument did not matter. Its July filing maintained that members’ financial interests are consistent with the Controlled Substances Act because drug testing deters drug use and helps employers maintain safe workplaces. The association argued that higher review costs would force some clients to drop marijuana testing, while smaller providers could be driven out of business.

This is the rare federal dispute in which both sides agree exactly what the business risk is.

They merely disagree on whether the Controlled Substances Act was intended to provide revenue protection for companies selling THC detection.

The Department of Justice says no.

The THC detection companies have consulted their THC detection companies and reached a different result.

MMJ International Joins the Bagholder Call

NDASA is not alone in seeking a stay.

Its partner in the motion is MMJ International Holdings and affiliated companies, a cannabinoid pharmaceutical venture that says it spent eight years and more than $10 million pursuing federal approvals. MMJ argues that the partial rescheduling order destroys its first-mover advantage by allowing state-licensed medical cannabis operators to compete under Schedule III after MMJ spent years navigating the DEA and FDA pathway.

MMJ’s grievance is almost beautiful.

The company followed a federal pathway so slow, expensive and hostile that competitors built entire state-regulated markets while it was still collecting paperwork. Now that the federal government has moved some of those competitors into Schedule III, MMJ wants the court to restore the obstacle course because it already paid admission.

This is sunk-cost prohibition.

MMJ has no approved cannabis medicine currently competing in the market, a point DOJ used to challenge its claim of competitor standing. The company nevertheless argues that state medical operators are receiving an unfair advantage because they did not spend eight years and $10 million attempting to satisfy the federal agencies that kept cannabis research trapped inside a regulatory meat grinder.

In most industries, a company that spends a decade developing no marketable product while competitors serve millions of customers holds an emergency board meeting.

In cannabis, it hires lawyers and asks the government to re-illegalize the competition.

MMJ and NDASA therefore make natural partners. One fears losing money because fewer people may be punished for cannabis use. The other fears losing money because more companies may be permitted to work with cannabis legally.

Together, they form a diversified portfolio of federal dysfunction.

William Barr Returns to the Prohibition Desk

The lawsuit filed by NDASA and Smart Approaches to Marijuana was signed by attorneys from Torridon Law, where former Attorney General William Barr is a partner. SAM announced earlier in 2026 that it had retained the firm to fight rescheduling after President Trump directed federal officials to accelerate the process.

Barr previously led the Justice Department during Trump’s first administration. He is now affiliated with lawyers representing organizations suing Trump’s current Justice Department over a cannabis reform initiated by Trump.

Federal marijuana policy has become so circular that the former attorney general can bill against the present attorney general for implementing the president they both served.

That is not a conflict.

That is government alumni networking.

SAM, led by Kevin Sabet, has spent years warning that cannabis reform is driven by corporations seeking profit. The organization is now litigating alongside a trade association that told a court its members could lose at least 35 percent of their revenue and a pharmaceutical venture worried that reform will produce unwanted competition.

The prohibition movement has finally confronted Big Marijuana with an unbeatable moral authority: Big Urine and Pre-Revenue Pharma.

The Safety-Sensitive Fig Leaf

NDASA’s strongest arguments involve genuinely safety-sensitive work, particularly federally regulated transportation. Nobody wants an impaired pilot, truck driver, train operator or heavy-equipment operator. Rescheduling does create difficult questions about how medical cannabis should interact with workplace rules, disability law, state protections and federal testing requirements.

But the industry frequently presents the most dangerous occupation imaginable, then uses it to defend marijuana testing everywhere else.

The crane operator becomes the moral spokesman for the marketing coordinator.

The airline pilot becomes the evidentiary basis for testing an entry-level software developer.

The school bus driver is marched into every policy debate so a call-center applicant can continue being screened for a legal weekend gummy.

Even after the partial rescheduling order, Department of Transportation guidance states that a medical review officer cannot currently verify a marijuana-positive result as negative merely because an employee claims state-licensed medical use. State-dispensed marijuana is not treated as an FDA-approved drug for that purpose. Federally regulated transportation testing has not simply evaporated because Blanche signed an order.

That makes NDASA’s broad commercial panic more revealing.

The immediate threat is not that every safety rule disappears. The threat is that employers outside the strictest federal programs may begin asking whether marijuana testing is worth the cost, legal complexity, hiring friction and talent loss.

Once customers ask that question, the testing industry must defend its product on utility rather than inherited fear.

No wonder it sued.

Human Capital, Extracted Into a Cup

The drug-testing industry’s financial concern is easy to quantify. A 35 percent revenue decline fits neatly into a declaration.

The worker’s cost is more scattered.

It appears as the job offer withdrawn after lawful off-duty use. The medical patient forced to choose between treatment and employment. The applicant who remains unemployed despite never arriving impaired. The employee ordered into humiliating observation procedures because a specimen was deemed suspicious. The qualified candidate rejected by an employer that does not test executives, board members or outside consultants with the same enthusiasm.

These costs rarely appear in the industry’s economic model because the worker is not the customer.

The worker is the specimen.

Drug testing is purchased by institutions, administered by vendors and imposed on individuals who generally have no negotiating power in the transaction. That arrangement allows every participant to describe the process as neutral. The laboratory reports chemistry. The medical review officer interprets the result. The employer applies policy. The consultant updates the handbook. Nobody personally fires the employee. The workflow does it.

Cannabis reform threatens that machinery by adding context.

Was the use medical?

Was it lawful under state law?

Was the worker impaired?

Is the position safety-sensitive?

Does the policy measure actual risk?

Could the employer retain qualified workers without inspecting their urine for historical evidence?

Those questions are expensive because they may reduce testing volume.

The old system required only one question: Did the cup catch weed?

Revised Analyst Guidance

From a financial perspective, NDASA has identified a legitimate sector risk.

Its members participate in a market where marijuana positives produce substantial recurring revenue. Federal recognition of medical use may cause customers to reconsider testing, complicate medical review and weaken the automatic connection between THC detection and workplace punishment. Smaller providers with concentrated exposure to marijuana-positive reviews could face material pressure.

Boof du Jour therefore issues the following analyst guidance:

Drug-testing firms with heavy exposure to THC positives: Sell.

Medical review practices dependent on Schedule I simplicity: Sell.

Consultants specializing in policies written before state legalization: Sell.

Law firms billing every side of federal cannabis dysfunction: Strong Buy.

Workers hoping employment decisions might someday depend on actual performance: Speculative Hold.

The court has not yet ruled on the request to stay the April order. The broader litigation remains pending, as do questions about the Justice Department’s legal authority, administrative procedure and the structure of the partial rescheduling regime.

Those legal issues deserve serious review.

The commercial argument deserves exactly the review it has received.

Congress did not pass the Controlled Substances Act to guarantee permanent income for companies that find marijuana in urine. The Constitution does not contain a Medical Review Officer Full Employment Clause. No business is entitled to freeze drug policy at 1970 because its revenue forecast performs poorly under medical reality.

The drug-testing industry spent decades insisting cannabis users needed to accept the consequences of their choices.

Now cannabis reform has appeared in its sample cup.

And the industry would like to speak with the manager.